Pharmacotherapy for Substance Use Disorder

Recently, the U.S. Congress enacted changes to the requirements for obtaining and maintaining a federal Drug Enforcement Agency registration that allows prescribing of controlled substances. On December 29, 2022, the Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners on the treatment and management of patients with opioid or other substance use. While that requirement is intended to insure that prescribers are treating opioid addictions appropriately, it goes beyond Schedule II narcotics; these prescribers may need additional education about overall substance abuse disorders (SUD), including alcohol. Many primary care physicians are lacking in the education and awareness of their options in diagnosing and treating patients for SUD, despite the fact that many options exist.

Who can attend

Registration is limited to ISMS members, ISMIE and SEMPIC policyholders and their employed staff.

Presenter:

Kirk Moberg, M.D.

Learning objectives

At the conclusion of this activity, learners will be able to:

1. Summarize the pharmacology of the FDA approved medications used to treat substance use disorders.
2. Review the regulatory environment surrounding medications used to treat opioid use disorder.
3. Discuss the clinical aspects of specific medications used to treat substance use disorders.

Accreditation

The Illinois State Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit designation

The Illinois State Medical Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.